Literature DB >> 12764232

Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia.

C D Garlichs1, S Kozina, S Fateh-Moghadam, R Handschu, B Tomandl, C Stumpf, S Eskafi, D Raaz, A Schmeisser, A Yilmaz, J Ludwig, B Neundörfer, W G Daniel.   

Abstract

BACKGROUND AND
PURPOSE: Inflammation and hypercoagulability contribute to the development of acute cerebral ischemia. Both can be mediated by the CD40 system. This study investigated whether the CD40 system and related mediators are upregulated in patients with transient ischemic attack (TIA) or stroke.
METHODS: Seventeen patients with TIA, 60 patients with complete stroke, and 15 control subjects were investigated. CD154 and P-selectin were analyzed on platelets and CD40 on monocytes during and 3 months after acute cerebral ischemia by double-label flow cytometry. Blood concentrations of soluble CD154 and monocyte chemoattractant protein-1 (MCP-1) were evaluated.
RESULTS: Our main findings are as follows: (1) patients with acute cerebral ischemia showed a significant increase of CD154 on platelets and CD40 on monocytes compared with controls; (2) plasma levels of soluble CD154 were significantly higher in these patients; (3) these patients had significantly higher numbers of prothrombotic platelet-monocyte aggregates; (4) the chemoattractant MCP-1 was significantly elevated in cerebral ischemia; and (5) at 3 months' follow-up, upregulation of CD154 still persisted in patients with previous acute cerebral ischemia.
CONCLUSIONS: Patients with acute cerebral ischemia show upregulation of the CD40 system, which might contribute to the known proinflammatory, proatherogenic, and prothrombotic milieu found in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764232     DOI: 10.1161/01.STR.0000074032.64049.47

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

1.  Thrombophilia in ischemic stroke subtypes: implications for treatment.

Authors:  Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  Blood biologic markers of stroke: improved management, reduced cost?

Authors:  Alison E Baird
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

3.  Soluble CD40 ligand levels in acute pulmonary embolism: a prospective, randomized, controlled study.

Authors:  Zeynettin Kaya; Kurtulus Ozdemir; Mehmet Kayrak; Enes Elvin Gul; Gokhan Altunbas; Cetin Duman; Aysel Kiyici
Journal:  Heart Vessels       Date:  2011-04-14       Impact factor: 2.037

4.  Inflammation after stroke: mechanisms and therapeutic approaches.

Authors:  Muzamil Ahmad; Steven H Graham
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

Review 5.  CD40/CD40L system and vascular disease.

Authors:  F Santilli; S Basili; P Ferroni; G Davì
Journal:  Intern Emerg Med       Date:  2007-11-28       Impact factor: 3.397

6.  CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.

Authors:  Guohong Li; John M Sanders; Melissa H Bevard; Zhiqi Sun; James W Chumley; Elena V Galkina; Klaus Ley; Ian J Sarembock
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 7.  Inflammatory markers and stroke.

Authors:  Mitchell S V Elkind
Journal:  Curr Cardiol Rep       Date:  2009-01       Impact factor: 2.931

8.  The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke.

Authors:  M S V Elkind; J M Luna; C S Coffey; L A McClure; K M Liu; S Spitalnik; M C Paik; A Roldan; C White; R Hart; O Benavente
Journal:  Int J Stroke       Date:  2010-04       Impact factor: 5.266

9.  Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation.

Authors:  F Angelico; C Alessandri; D Ferro; P Pignatelli; M Del Ben; S Fiorello; R Cangemi; L Loffredo; F Violi
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

Review 10.  Stroke and T-cells.

Authors:  Thiruma V Arumugam; D Neil Granger; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.